Search results
Showing 1666 to 1680 of 2188 results for guidelines
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
phosphate and amino acid recommendations (1.5.11, 1.5.2 and 1.5.3) in this guideline are appropriate. However, because the evidence was...
NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
Read NICE's patient and public involvement policy.
Read NICE's patient and public involvement policy.
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)
Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
This guideline has been updated and replaced by NICE guideline NG92.
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)
This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]